Magnetic double-J stent: Evaluation of tolerance and impact on quality of life compared to traditional double-J stent.

INTRODUCTION: The placement of a ureteral stent is one of the most widely performed procedures in urology. It can have a negative impact on the patients' quality of life, requiring a cystoscopy for its removal. The objective of this study is to evaluate the symptoms and impact on quality of life derived from the use of a magnetic double-J stent (Black Star®) and compare them to those presented in patients with a traditional double-J stent (OptiMed®). MATERIAL AND METHODS: We conducted a comparative, prospective, randomized study in 46 patients who underwent ureterorenoscopy with double-J stent placement between August 2019 and June 2020. Of all patients included, 23 had a traditional double-J stent placed (group A) and 23 had a magnetic double-J stent (group B) placed. We evaluated the results of the Ureteral Stent Symptom Questionnaire (USSQ) in both groups, assessed the technical difficulty related to stent removal and the pain during the procedure using the Visual Analogue Scale (VAS). We also reviewed the need for medical attention due to problems related to the stent or after its removal. RESULTS: There were no statistically significant differences between groups regarding the answers in the USSQ and the complications related to the use of the stent. Group B showed less pain (1.52 vs. 4, VAS, p = 0.001) and less difficulty during removal (1.61 vs. 3, p < 0.001) associated with a shorter procedure duration (11.65 min vs. 22.17 min p < 0.001). CONCLUSIONS: The tolerance shown by the use of magnetic double-J is comparable to the tolerance of traditional stent, since it does not cause an increase in urinary symptoms nor worsens the quality of life of patients during its use.

Treatment for rectourethral fistulas after radical prostatectomy with biological material interposition through a perineal access.

INTRODUCTION: Rectal injury is a rare complication after extraperitoneal laparoscopic radical prostatectomy. The development of rectourethral fistulas (URF) from rectal injuries is one of the most feared and of more complex resolution in urology. MATERIAL AND METHODS: Between 2013 and 2020 we have operated on a total of 5 patients with URF after extraperitoneal endoscopic radical prostatectomy through a perineal access using the interposition of biological material. All fistulas had a diameter of less than 6 mm at endoscopy and were less than 6 cm apart from the anal margin. RESULTS: The mean age of the patients was 64 years old. All patients had a previous bowel and urinary diversion for at least 3 months. Under general anesthesia and with the patient in a forced lithotomy position, fistulorraphy and interposition of biological material of porcine origin (lyophilized porcine dermis [Permacol®]) were performed through a perineal access. Mean operative time was 174 min (140-210). Most patients were discharged on the third postoperative day. The bladder catheter was left in place for a mean of 40 days (30-60). Prior to its removal, cystography and a Gastrografin® barium enema were performed, showing resolution of the fistula in all cases. CONCLUSIONS: The interposition of biological material from porcine dermis through perineal approach is a safe alternative with good results in patients submitted to urethrorectal fistulorraphy after radical prostatectomy.

Catéter doble J magnético: evaluación de la tolerancia e impacto en la calidad de vida en comparación con el catéter doble J tradicional / Magnetic double-J stent: evaluation of tolerance and impact on quality of life compared to traditional double-J stent

Introducción: La colocación de un catéter doble J (DJ) es uno de los procedimientos más realizados en urología. Puede causar un impacto negativo en la calidad de vida, siendo necesaria una cistoscopia para su extracción. El objetivo de este estudio es evaluar la sintomatología e impacto en la calidad de vida derivados del uso del catéter DJ magnético (Black Star®) y compararla con la del DJ tradicional (OptiMed®).Material y métodosRealizamos un estudio comparativo, prospectivo y aleatorizado en 46 pacientes sometidos a ureterorrenoscopia (URS) en quienes se colocó un DJ entre agosto del 2019 y junio del 2020. De los pacientes incluidos, 23 llevaron un DJ tradicional (grupo A) y 23 un DJ magnético (grupo B). Valoramos en ambos grupos los resultados del cuestionario de síntomas de catéter ureteral (USSQ). Evaluamos el dolor de la extracción mediante la escala visual analógica (EVA) y la dificultad de la retirada. Revisamos la necesidad de atención médica por problemas relacionados con el catéter o surgidos tras la extracción.ResultadosNo observamos diferencias estadísticamente significativas en el cuestionario USSQ, ni en las complicaciones. El grupo B presentó: menor dolor de la extracción (EVA de 1,52 vs. 4, p = 0,001), menor dificultad en la retirada (1,61 vs. 3, p < 0,001) y menor tiempo de extracción (11,65 vs. 22,17 min p < 0,001).ConclusionesEl DJ magnético es un catéter ureteral que presenta una tolerancia equiparable a los tradicionales, ya que no genera un incremento de la sintomatología urinaria ni empeora la calidad de vida de los pacientes durante su uso. (AU)

Introduction: The placement of a ureteral stent is one of the most widely performed procedures in urology. It can have a negative impact on the patients’ quality of life, requiring a cystoscopy for its removal. The objective of this study is to evaluate the symptoms and impact on quality of life derived from the use of a magnetic double-J stent (Black Star ®) and compare them to those presented in patients with a traditional double-J stent (OptiMed®).Material and methodsWe conducted a comparative, prospective, randomized study in 46 patients who underwent ureterorenoscopy with double-J stent placement between August 2019 and June 2020. Of all patients included, 23 had a traditional double-J stent placed (group A) and 23 had a magnetic double-J stent (group B) placed. We evaluated the results of the Ureteral Stent Symptom Questionnaire (USSQ) in both groups, assessed the technical difficulty related to stent removal and the pain during the procedure using the Visual Analogue Scale (VAS). We also reviewed the need for medical attention due to problems related to the stent or after its removal.ResultsThere were no statistically significant differences between groups regarding the answers in the USSQ and the complications related to the use of the stent. Group B showed less pain (1,52 vs. 4, VAS, p = 0.001) and less difficulty during removal (1,61 vs. 3, p < 0,001) associated with a shorter procedure duration (11,65 min vs. 22,17 min p < 0,001).ConclusionsThe tolerance shown by the use of magnetic double-J is comparable to the tolerance of traditional stent, since it does not cause an increase in urinary symptoms nor worsens the quality of life of patients during its use. (AU)

Tratamiento de las fístulas uretrorrectales tras prostatectomía radical mediante la interposición de material biológico vía perineal / Treatment for rectourethral fistulas after radical prostatectomy with biological material interposition through a perineal access

Introducción: La lesión rectal es una complicación infrecuente de la prostatectomía radical laparoscópica extraperitoneal. El desarrollo de fístulas uretrorrectales (FUR), a partir de lesiones rectales, resulta uno de los problemas más temidos y de más compleja resolución en urología.Material y métodosEntre 2013 y 2020 hemos intervenido a un total de cinco pacientes con FUR tras prostatectomía radical endoscópica extraperitoneal, mediante un abordaje perineal utilizando la interposición de material biológico. Todas las fístulas presentaron un diámetro menor de 6 mm en la endoscopia y se encontraban a menos de 6 cm del margen anal.ResultadosLa media de edad de los pacientes fue 64 años. Todos los pacientes llevaban al menos tres meses de derivación intestinal y urinaria previas. Bajo anestesia general, y con el paciente en posición de litotomía forzada mediante un acceso perineal, se realizó fistulorrafia e interposición de material biológico de origen porcino (dermis porcina liofilizada [Permacol®, Medtronic]). La duración media de la cirugía fue de 174 min (140-210). La mayoría de los pacientes fueron dados de alta al tercer día postoperatorio. La sonda vesical se mantuvo una media de 40 días (30-60). Previa a la retirada de la misma, se realizó cistografía y enema opaco con Gastrografin®, que mostró resolución de la fístula en todos los casos.ConclusionesLa interposición de material biológico procedente de dermis porcina mediante abordaje perineal es una alternativa segura y con buenos resultados en pacientes sometidos a fistulorrafia uretrorrectal tras prostatectomía radical. (AU)

Introduction: Rectal injury is a rare complication after extraperitoneal laparoscopic radical prostatectomy. The development of rectourethral fistulas (URF) from rectal injuries is one of the most feared and of more complex resolution in urology.Material and methodsBetween 2013 and 2020 we have operated on a total of 5 patients with URF after extraperitoneal endoscopic radical prostatectomy through a perineal access using the interposition of biological material. All fistulas had a diameter of less than 6 mm at endoscopy and were less than 6 cm apart from the anal margin.ResultsThe mean age of the patients was 64 years old. All patients had a previous bowel and urinary diversion for at least 3 months. Under general anesthesia and with the patient in a forced lithotomy position, fistulorraphy and interposition of biological material of porcine origin (lyophilized porcine dermis [Permacol®]) were performed through a perineal access. Mean operative time was 174 minutes (140-210). Most patients were discharged on the third postoperative day. The bladder catheter was left in place for a mean of 40 days (30-60). Prior to its removal, cystography and a Gastrografin® barium enema were performed, showing resolution of the fistula in all cases.ConclusionsThe interposition of biological material from porcine dermis through perineal approach is a safe alternative with good results in patients submitted to urethrorectal fistulorraphy after radical prostatectomy. (AU)

Análisis de coste efectividad de fesoterodina comparado con mirabegron en el marco de tratamiento de primera línea para vejiga hiperactiva con incontinencia urinaria de urgencia, desde la perspectiva del Sistema Nacional de Salud español / Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective

Objetivos: Evaluar el coste-efectividad del tratamiento de primera línea de la vejiga hiperactiva (VH) con fesoterodina en relación con mirabegron, desde la perspectiva del Sistema Nacional de Salud (SNS) español. Métodos: Se desarrolló un modelo de árbol de decisión para representar un proceso clínico típico de tratamiento de 52 semanas para un paciente con VH con incontinencia urinaria de urgencia (IUU) iniciando el tratamiento de primera línea con fesoterodina 4 mg, incluyendo valoración opcional a 8 mg frente a mirabegron 50 mg. Los datos de eficacia se obtuvieron de un metaanálisis de tratamiento indirecto bayesiano. Los pacientes con IUU de menos de un episodio/día fueron definidos como respondedor al tratamiento, y la persistencia se evaluó en las semanas 4, 12 y 24. En la semana 12 los no respondedores interrumpieron el tratamiento de forma permanente. Los años de vida ajustados por calidad (AVAC) se calcularon sobre la base de tiempo de permanencia en estados de respondedores y no respondedores. Los costes de la medicina relacionada con la VH y atención médica, incluyendo visitas médicas, pruebas de laboratorio, compresas para la incontinencia y comorbilidades (fractura, infección de la piel, infecciones del tracto urinario y depresión) se modelaron y expresaron en 2015 Euros. Resultados: En la semana 52 el porcentaje de respondedores fue de 20,8% para los pacientes que comienzan con 4mg de fesoterodina, que opcionalmente valoró a 8 mg, y de 19,4% para los pacientes tratados con mirabegron. Los AVAC fueron ligeramente superiores con fesoterodina que con mirabegron (0,7703 vs. 0,7668, diferencia = 0,0035). El tratamiento con fesoterodina también tenía costes totales ligeramente mayores que mirabegron (3.296€ vs. 3.217, diferencia = 79€), lo que resulta en un coste de 22.523/AVAC€ ganado para la fesoterodina frente al mirabegron. El análisis de sensibilidad probabilístico confirmó la ligera ventaja de la fesoterodina, con un 61,1% de probabilidad de ser rentable en la disposición a pagar de 30.000€ para un umbral de AVAC. Conclusiones: Dada la relativamente pequeña diferencia de coste de un año entre los 2 tratamientos, la fesoterodina puede considerarse una opción rentable en relación con mirabegron para el manejo de primera línea de la VH con IUU en España

Objectives: To evaluate the cost-effectiveness of first-line treatment of Overactive Bladder (OAB) with fesoterodine relative to mirabegron, from the Spanish National Health System (NHS) perspective. Methods: A decision tree model was developed to represent a typical clinical process of 52-week of treatment for an OAB patient with urge urinary incontinence (UUI) initiating first-line therapy with fesoterodine 4 mg, including optional titration to 8mg, vs.mirabegron 50 mg. Efficacy data were obtained from a Bayesian indirect treatment meta-analysis. Patients with UUI of less than one episode/day were defined as treatment responder and persistence was assessed at weeks 4, 12 and 24. At week 12, non-responders discontinued treatment permanently. Quality-adjusted life years (QALYs) were calculated based on time spent in responder and non-responder states. OAB-related drug and medical care costs including physician visits, laboratory tests, incontinence pads, and comorbidities (fracture, skin infection, urinary tract infections and depression) were modeled and expressed in Euros 2015. Results: At week 52, the percentage of responders was 20.8% for patients starting on fesoterodine 4 mg who optionally titrated to 8 mg and 19.4% for patients treated with mirabegron. QALYs were slightly higher with fesoterodine than mirabegron (0.7703 vs. 0.7668, difference = 0.0035). Fesoterodine treatment also had slightly higher total costs than mirabegron (3,296 € vs. 3,217, difference = 79 €), resulting in a cost of 22,523/QALYEuros gained for fesoterodine versus mirabegron. Probabilistic sensitivity analysis confirmed the slight advantage of fesoterodine with a 61.1% probability of being cost-effective at the 30,000€ willingness-to-pay for 1QALY threshold. Conclusions: Given the relatively small 1-year cost difference between the two treatments, fesoterodine can be considered a cost-effective option relative to mirabegron for the first-line management of OAB with UUI in Spain

Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective. / Análisis de coste efectividad de fesoterodina comparado con mirabegron en el marco de tratamiento de primera línea para vejiga hiperactiva con incontinencia urinaria de urgencia, desde la perspectiva del Sistema Nacional de Salud español.

OBJECTIVES: To evaluate the cost-effectiveness of first-line treatment of Overactive Bladder (OAB) with fesoterodine relative to mirabegron, from the Spanish National Health System (NHS) perspective. METHODS: A decision tree model was developed to represent a typical clinical process of 52-week of treatment for an OAB patient with urge urinary incontinence (UUI) initiating first-line therapy with fesoterodine 4mg, including optional titration to 8mg, vs.mirabegron 50mg. Efficacy data were obtained from a Bayesian indirect treatment meta-analysis. Patients with UUI of less than one episode/day were defined as treatment responder and persistence was assessed at weeks 4, 12 and 24. At week 12, non-responders discontinued treatment permanently. Quality-adjusted life years (QALYs) were calculated based on time spent in responder and non-responder states. OAB-related drug and medical care costs including physician visits, laboratory tests, incontinence pads, and comorbidities (fracture, skin infection, urinary tract infections and depression) were modeled and expressed in €2015. RESULTS: At week 52, the percentage of responders was 20.8% for patients starting on fesoterodine 4mg who optionally titrated to 8mg and 19.4% for patients treated with mirabegron. QALYs were slightly higher with fesoterodine than mirabegron (0.7703vs. 0.7668, difference=0.0035). Fesoterodine treatment also had slightly higher total costs than mirabegron (3,296€vs. 3,217, difference=79€), resulting in a cost of 22,523/QALY€ gained for fesoterodine versus mirabegron. Probabilistic sensitivity analysis confirmed the slight advantage of fesoterodine with a 61.1% probability of being cost-effective at the 30,000€ willingness-to-pay for 1QALY threshold. CONCLUSIONS: Given the relatively small 1-year cost difference between the two treatments, fesoterodine can be considered a cost-effective option relative to mirabegron for the first-line management of OAB with UUI in Spain.

Beneficio terapéutico tras cambiar tolterodina por otros nuevos antimuscarínicos / Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents

Objetivos: Explorar en la práctica clínica diaria el beneficio clínico y del paciente conseguido tras cambiar su primer tratamiento para la vejiga hiperactiva (VH) con tolterodina de liberación prolongada (LP), por otro antimuscaríninico de última generación. Materiales y métodos: Análisis post hoc de un estudio observacional, multicéntrico retrospectivo y transversal. Se incluyeron pacientes adultos de ambos sexos, con VH y puntuación OAB-V8 ≥ 8, con respuesta insuficiente al tratamiento previo con tolterodina LP sustituido por fesoterodina o solifenacina en los 3-4 meses previos. Se seleccionaron 92 pacientes para cada grupo de tratamiento, emparejados (1:1) según probabilidad condicionada utilizando el propensity score. Se valoraron el beneficio del cambio percibido por el médico y el paciente mediante las escalas de Impresión clínica global de mejoría (ICG-M) y del Beneficio del tratamiento (TBS) respectivamente. También se analizaron el grado de preocupación, la molestia y el impacto en la vida diaria de la VH, el grado de satisfacción y la preferencia por la medicación actual. Resultados: Fesoterodina proporcionó una mejora significativamente mayor que solifenacina en cuanto a beneficio terapéutico percibido por el médico según la ICG-M. El 96,7% de los pacientes tratados con fesoterodina vs. 81,6% con solifenacina mostraron una puntuación de mejoría en la TBS (p < 0,05). La fesoterodina también resultó mejor valorada que la solifenacina en cuanto a la satisfacción y preferencia por el nuevo tratamiento (93,4 vs. 78,2%, p < 0,05). Conclusiones: En la práctica clínica diaria el cambio de tolterodina LP a fesoterodina parece proporcionar mayores beneficios tanto desde el punto de vista del médico como del paciente, comparado con el que aporta solifenacina

Objectives: To explore in the daily clinical practice setting that antimuscarinic, Fesoterodine or Solifenacin, provides a greater clinical benefit after changing their prior Overactive Bladder (OAB) therapy with tolterodine extended-release (ER) to other novel antimuscarinic agents. Material and methods: A post-hoc analysis of data from an observational multicenter, cross sectional, retrospective study. Adult patients of both sexes, with OAB and OAB-V8 score≥8, who switched to fesoterodine or solifenacin within the 3-4 months before study visit from their priortolterodine-ER-based therapy due to poor response were included. 92 patients were selected for each treatment group, matched (1:1) according to conditioned probability using the propensity score. Benefit of treatment change perceived by the physician and patient was evaluated by means of the Clinical Global Impression of Improvement subscale (CGI-I) and Treatment Benefit Scale (TBS), respectively. Degree of worry, bother and interference with daily living activities due to urinary symptoms, level of satisfaction, and preference for current treatment were also assessed. Results: Fesoterodine provided a significantly greater improvement than solifenacina in terms of therapeutic benefit perceived by the physician according to ICG-I. 96.7% of the patients on fesoterodine treatment vs. 81.6% of the solifenac in group showed a score of improvementin TBS (P < 0.05). Fesoterodine was also better rated than solifenacin with regard to satisfaction and preference for the new treatment (93.4 vs. 78.2% P < 0.05). Conclusions: In daily clinical practice the switch from tolterodine LP to fesoterodine seems to provide greater benefits both from the physician’s and the patient’s point of view compared with those provided by solifenacin

Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.

OBJECTIVES: To explore in the daily clinical practice setting that antimuscarinic, Fesoterodine or Solifenacin, provides a greater clinical benefit after changing their prior Overactive Bladder (OAB) therapy with tolterodine extended-release (ER) to other novel antimuscarinic agents. MATERIAL AND METHODS: A post-hoc analysis of data from an observational multicenter, cross-sectional, retrospective study. Adult patients of both sexes, with OAB and OAB-V8 score≥8, who switched to fesoterodine or solifenacin within the 3-4 months before study visit from their prior tolterodine-ER-based therapy due to poor response were included. 92 patients were selected for each treatment group, matched (1:1) according to conditioned probability using the propensity score. Benefit of treatment change perceived by the physician and patient was evaluated by means of the Clinical Global Impression of Improvement subscale (CGI-I) and Treatment Benefit Scale (TBS), respectively. Degree of worry, bother and interference with daily living activities due to urinary symptoms, level of satisfaction, and preference for current treatment were also assessed. RESULTS: Fesoterodine provided a significantly greater improvement than solifenacina in terms of therapeutic benefit perceived by the physician according to ICG-I. 96.7% of the patients on fesoterodine treatment vs. 81.6% of the solifenacin group showed a score of improvement in TBS (P<.05). Fesoterodine was also better rated than solifenacin with regard to satisfaction and preference for the new treatment (93.4 vs. 78.2% P<.05). CONCLUSIONS: In daily clinical practice the switch from tolterodine LP to fesoterodine seems to provide greater benefits both from the physician's and the patient's point of view compared with those provided by solifenacin.

[Assessment of reasons for overactive bladder treatment change]. / Evaluación de los motivos del cambio de tratamiento para la vejiga hiperactiva.

OBJECTIVES: although efficacious, some patients do not respond optimally to overactive bladder (OAB) treatment. The objective of this study was to identify the reasons why some patients do not respond and to look for reasons for changes in treatment and patient satisfaction with the new treatment. MATERIALS AND METHODS: epidemiological, cross-sectional, non-interventional study to determine the reasons for OAB treatment switching and satisfaction with such OAB treatment switch. OAB patients (OAB-V8≥8), 18 years or more, who had modified their treatment during the previous 3-4 months, were recruited. Demographic data, symptoms, previous, current and concomitant treatments, reasons for treatment switch, clinical global impression (CGI) on disease severity and symptom improvement, Morinsky Green questionnaire, satisfaction with treatment, treatment preference and treatment benefit scale (TBS) were compared. RESULTS: out of 3,365 successive patients, 2,038 (61%) were eligible (61.1±11.2 years; 77% women). The physician decided to switch in 69% of the cases and 31% of patients asked for a change in treatment. Reasons for switching were lack of clinical benefit (60%), side effects (24%), patients' request (8%), non-compliance (6%) and other (2%). 52% of patients complied with new treatment. According to the CGI, 65.4% showed improvement with respect to their previous treatment. 60% were quite/very satisfied with current treatment, 91% preferred it to their previous treatment and 93% reported that their symptoms had improved. CONCLUSIONS: the lack of clinical benefit is the main reason for changing OAB treatment. Most of the patients that switched prefer their new treatment.

Evaluación de los motivos del cambio de tratamiento para la vejiga hiperactiva / Assessment of reasons for overactive bladder treatment change

Objetivos: aunque el tratamiento de la vejiga hiperactiva (VH) es eficaz, muchos pacientes no responden, por lo que interesa estudiar los motivos de cambio de tratamiento y la satisfacción del paciente con el nuevo tratamiento. Material y métodos: estudio epidemiológico, transversal, no intervencionista para determinar los motivos del cambio de tratamiento en VH y la satisfacción con dicho cambio. Se reclutaron pacientes con VH (OAB-V8 ≥ 8), de ambos sexos, mayores de 18 años, que habían modificado su tratamiento en los 3-4 meses previos. Se recogieron datos demográficos, síntomas, tratamiento previo, actual y concomitante, motivo del cambio, impresión clínica global (ICG) de gravedad y de mejoría, cuestionario Morinsky Green, satisfacción con el tratamiento, preferencia del mismo y la escala del beneficio del tratamiento (TBS). Resultados: de 3.365 pacientes reclutados, 2.038 (61%) fueron evaluables (61,1±11,2 años; 77% mujeres). El médico solicitó el cambio de tratamiento en un 69% y el paciente en un 31% por motivos de falta de beneficio clínico (60%), efectos secundarios (24%), petición del paciente (8%), incumplimiento terapéutico (6%) y otros (2%). El 52% de los pacientes cumplió con el nuevo tratamiento. Según ICG, el 65,4% presentó mejoría respecto al tratamiento anterior. Un 60% de los pacientes se mostró bastante/muy satisfecho con el tratamiento actual, un 91% lo prefirió al previo y un 93% opinó que sus síntomas habían mejorado. Conclusiones: la falta de beneficio clínico es el principal motivo del cambio de tratamiento de la VH. La mayoría de los pacientes prefieren el nuevo tratamiento (AU)

Objectives: although efficacious, some patients do not respond optimally to overactive bladder (OAB) treatment. The objective of this study was to identify the reasons why some patients do not respond and to look for reasons for changes in treatment and patient satisfaction with the new treatment. Materials and methods: epidemiological, cross-sectional, non-interventional study to determine the reasons for OAB treatment switching and satisfaction with such OAB treatment switch. OAB patients (OAB-V8≥8), 18 years or more, who had modified their treatment during the previous 3-4 months, were recruited. Demographic data, symptoms, previous, current and concomitant treatments, reasons for treatment switch, clinical global impression (CGI) on disease severity and symptom improvement, Morinsky Green questionnaire, satisfaction with treatment, treatment preference and treatment benefit scale (TBS) were compared. Results: out of 3,365 successive patients, 2,038 (61%) were eligible (61.1±11.2 years; 77% women). The physician decided to switch in 69% of the cases and 31% of patients asked for a change in treatment. Reasons for switching were lack of clinical benefit (60%), side effects (24%), patients’ request (8%), non-compliance (6%) and other (2%). 52% of patients complied with new treatment. According to the CGI, 65.4% showed improvement with respect to their previous treatment. 60% were quite/very satisfied with current treatment, 91% preferred it to their previous treatment and 93% reported that their symptoms had improved. Conclusions: the lack of clinical benefit is the main reason for changing OAB treatment. Most of the patients that switched prefer their new treatment (AU)

Fotovaporización prostática (FVP) mediante láser verde. Ventajas quirúrgicas en pacientes de riesgo / Greenlight Laser Photoselective vaporization of the prostate (PVP). Surgical advantages in risk patients

Cada vez son más frecuentes en nuestras consultas los pacientes diagnosticados de HBP en los que al indicar la intervención quirúrgica, se plantean limitaciones por la toma de medicación concomitante, edad, morbilidad asociada o condiciones psicosociales. La RTU de próstata, aun siendo el patrón quirúrgico de referencia, en este grupo de pacientes ancianos y de alto riesgo, no está exenta de complicaciones como la posibilidad de reabsorción, sangrado e incluso transfusión en un porcentaje de casos. La fotovaporización prostática mediante láser puede ser una alternativa válida en este subgrupo de pacientes. Revisamos nuestra experiencia en este procedimiento, así como lo publicado al respecto y describimos recomendaciones técnicas que consideramos útiles para evitar en lo posible complicaciones durante la cirugía o en el postoperatorio inmediato (AU)

It is more and more common to have patients in our clinics with the diagnosis of BPH and indication for surgery who present limitations due to their medications, age, associated morbidity or psychosocial conditions. Transurethral resection of the prostate, though it is the surgical standard of reference, is not free from complications such as reabsorption syndrome, bleeding, or even blood transfusion in a percentage of cases. Laser PVP may be a valid alternative in this subgroup of patients. We review our experience with this procedure, as well as the published articles on this topic, and describe technical recommendations we consider useful to avoid complications when possible during surgery or the immediate postoperative period (AU)

[Greenlight Laser Photoselective vaporization of the prostate (PVP). Surgical advantages in risk patients]. / Fotovaporización prostática (FVP) mediante láser verde. Ventajas quirúrgicas en pacientes de riesgo.

It is more and more common to have patients in our clinics with the diagnosis of BPH and indication for surgery who present limitations due to their medications, age, associated morbidity or psychosocial conditions. Transurethral resection of the prostate, though it is the surgical standard of reference, is not free from complications such as reabsorption syndrome, bleeding, or even blood transfusion in a percentage of cases. Laser PVP may be a valid alternative in this subgroup of patients. We review our experience with this procedure, as well as the published articles on this topic, and describe technical recommendations we consider useful to avoid complications when possible during surgery or the immediate postoperative period.

[Endoscopic treatment of the benign prostatic hyperplasia with local anesthesia and sedation in patients with high surgical or anaesthesical risk]. / Tratamiento endoscópico de la hiperplasia benigna de próstata bajo anestesia local-sedación en pacientes de alto riesgo.

INTRODUCTION AND OBJECTIVE: [corrected] The aging of the population causes an increase of the number of men affected by benign prostatic hyperplasia (BPH) with a large number of pathology associated that may limit its surgical treatment. In this study we try to show the effectiveness and security of local anaesthesia and sedation in the endoscopic treatment of the BPH in patients with high surgical-anaesthetic risk. METHODS: During the last 4 years, 38 patients underwent surgical treatment of BPH with ages between 78 and 86 years (average 81,4 +/- 3,2) with severe obstructive prostatic syndrome and high surgical-anaesthetic risk. 15 patients underwent, transurethral incision of prostate (TUIP) and in 23 patients, transurethral resection (TURP) was performed. The blockade anesthetic was made by transrectal periprostatic infiltration finger-guided with 10-15 millilitres of lidocaine 2%. During the procedure an intravenous perfusion of propofol and remifentanil was administered. The obtained results as well as the patient's satisfaction degree was evaluated by means of the elaboration of a questionnaire. RESULTS: The average length of the surgical treatment was of 12 +/- 5 minutes (rank 8 - 25), having itself not stated complications derived from the anesthetic technique. They referred a slight annoyance 4 patients (11%) that was treated increasing the rate of the sedative perfusión. The satisfaction's degree with the received treatment has been good in the 95% of patients. CONCLUSIONS: We considered that the TUIP as much as TURP made under local anesthesia with sedation are safe, effective methods and well tolerated, that fundamentally are indicated in aged patients and when the surgical-anesthetic risk is elevated.

Tratamiento endoscópico de la hiperplasia benigna de próstata bajo anestesia local-sedación en pacientes de alto riesgo / Endoscopic treatment of the benign prostatic hyperplasia with local anesthesia and sedation in patients with high surgical or anaesthesical risk

Introducción y objetivo: El envejecimiento de la población comporta un incremento del número de varones afectos de hiperplasia benigna de próstata (HBP) con múltiple patología asociada que limita su tratamiento quirúrgico. Con este estudio pretendemos poner de manifiesto la eficacia y seguridad del empleo de anestesia local-sedación para el tratamiento endoscópico de la HBP en pacientes de alto riesgo quirúrgico-anestésico. Método: Durante los últimos 4 años hemos intervenido a 38 pacientes con edades comprendidas entre 78 y 86 años (media 81,4 ± 3,2) con síndrome de prostatismo obstructivo severo y riesgo quirúrgico-anestésico elevado. En 15 pacientes se practicó incisión transuretral de próstata (ITUP) y en los 23 restantes resección transuretral (RTUP). El bloqueo anestésico se realizó mediante infiltración periprostática transrectal digito-dirigida con 10-15 ml de lidocaína al 2%. Durante el procedimiento se administró una perfusión intravenosa de propofol y remifentanilo. Se evalúan los resultados obtenidos así como el grado de satisfacción de los pacientes mediante la elaboración de un cuestionario. Resultados: La duración media de la intervención fue de 12 ± 5 minutos (rango 8 - 25), no habiéndose constatado complicaciones derivadas de la técnica anestésica. Refirieron una molestia leve 4 pacientes (11%) que se resolvió aumentando la velocidad de la perfusión sedante. El grado de satisfacción con el tratamiento recibido ha sido del 95%. Conclusiones: Consideramos que tanto la ITUP como RTUP realizadas bajo anestesia local-sedación son métodos seguros, eficaces y bien tolerados, que están fundamentalmente indicados en pacientes añosos y cuando el riesgo quirúrgico-anestésico es elevado

Introduction and objetive: The aging of the population causes an increase of the number of men affected by benign prostatic hyperplasia (BPH) with a large number of pathology associated that may limit its surgical treatment. In this study we try to show the effectiveness and security of local anaesthesia and sedation in the endoscopic treatment of the BPH in patients with high surgical- anaesthetic risk. Methods: During the last 4 years, 38 patients underwent surgical treatment of BPH with ages between 78 and 86 years (average 81,4± 3,2) with severe obstructive prostatic syndrome and high surgical-anaesthetic risk. 15 patients underwent, transurethral incision of prostate (TUIP) and in 23 patients, transurethral resection (TURP) was performed. The blockade anesthetic was made by transrectal periprostatic infiltration finger-guided with 10-15 millilitres of lidocaine 2%. During the procedure an intravenous perfusion of propofol and remifentanil was administered. The obtained results as well as the patient’s satisfaction degree was evaluated by means of the elaboration of a questionnaire . Results: The average length of the surgical treatment was of 12 ± 5 minutes (rank 8 - 25), having itself not stated complications derived from the anesthetic technique. They referred a slight annoyance 4 patients (11%) that was treated increasing the rate of the sedative perfusión. The satisfaction’s degree with the received treatment has been good in the 95% of patients. Conclusions: We considered that the TUIP as much as TURP made under local anesthesia with sedation are safe, effective methods and well tolerated, that fundamentally are indicated in aged patients and when the surgical-anesthetic risk is elevate

[Correction of the penile curvature in ambulatory surgery]. / Corrección del pene curvo en cirugía mayor ambulatoria.

OBJECTIVE: To evaluate the results obtained in the correction of the curved penis by means of Nesbit's technique during the four first years of integration of our Service in the Major Ambulatory Surgery Unit (CMA) of our Hospital. PATIENTS AND METHOD: From January of 2000 to April of 2004 we intervened in ambulatory regime 21 patient suffering from curved penis (12 congenital and 9 with Peyronie's disease) by means of Nesbit's technique. The surgical-anesthetic performed procedure is described and also the criteria of inclusion and discharge are evaluated, as well as the results obtained and the degree of satisfaction by means of the elaboration of a questionnaire. RESULTS: None of the patients needed entrance for intrasurgery nor postsurgery complications. Thus, we obtained a null incidence of complications with the exception of the inevitable shortening of the penis, clearly independent from the regime of out-patient's process. The degree of satisfaction with the received treatment has been superior to 95%. CONCLUSIONS: The practical totality of the susceptible patients for surgical correction of penile curvature are candidates to be included in a CMA program, improving obviously the relation cost-efficacy, not diminishing for that reason the welfare quality nor the degree of patient's satisfaction.

Corrección del pene curvo en cirugía mayor ambulatoria / Correction of the penile curvature in ambulatory surgery

Objetivo: Evaluar los resultados obtenidos en la corrección del pene curvo mediante la técnica de Nesbit durante los cuatro primeros años de integración de nuestro Servicio en la Unidad de Cirugía Mayor Ambulatoria (CMA) de nuestro Hospital. Pacientes y método: Desde enero de 2000 hasta abril de 2004 hemos intervenido en régimen ambulatorio a 21 pacientes afectos de pene curvo (12 congénito y 9 con enfermedad de Peyronie) mediante la técnica de Nesbit. Se describe el procedimiento quirúrgico-anestésico realizado y también se evalúan los criterios de inclusión y alta, así como los resultados obtenidos y el grado de satisfacción mediante la elaboración de un cuestionario. Resultados: Ninguno de los pacientes precisó ingreso por complicación intra ni postoperatoria. Así, hemos tenido una nula incidencia de complicaciones a excepción del inevitable acortamiento del pene, claramente independiente del régimen de ambulatorización del proceso. El grado de satisfacción con el tratamiento recibido ha sido superior al 95%. Conclusiones: La práctica totalidad de los pacientes susceptibles de corrección quirúrgica de incurvación peneana son candidatos a ser incluidos en un programa de CMA, mejorando ostensiblemente la relación costo-eficacia, no disminuyendo por ello la calidad asistencial ni el grado de satisfacción de los pacientes (AU)

Objective: To evaluate the results obtained in the correction of the curved penis by means of Nesbit’s technique during the four first years of integration of our Service in the Major Ambulatory Surgery Unit (CMA) of our Hospital. Patients and method: From January of 2000 to April of 2004 we intervened in ambulatory regime21 patient suffering from curved penis (12 congenital and 9 with Peyronie´s disease) by means of Nesbit’s technique. The surgical-anesthetic performed procedure is described and also the criteria of inclusion and discharge are evaluated, as well as the results obtained and the degree of satisfaction by means of the elaboration of a questionnaire. Results: None of the patients needed entrance for intrasurgery or postsurgery complications. Thus, we obtained a null incidence of complications with the exception of the inevitable shortening of the penis, clearly independent from the regime of out-patient’s process. The degree of satisfaction with the received treatment has been superior to 95%. Conclusions: The practical totality of the susceptible patients for surgical correction of penile curvature are candidates to be included in a CMA program, improving obviously the relation cost-efficacy, not diminishing for that reason the welfare quality nor the degree of patients’s satisfaction (AU)